On November 18, the 20th China Economic Forum, hosted by China Economic Weekly magazine under People's Daily, was successfully held at the Guangzhou Nansha International Convention Center.

The China Economic Forum is a major economic forum event hosted by China Economic Weekly magazine under People's Daily. Since its inception in 2001, it has had a broad influence across government, business, and academic circles.

It is reported that the theme of this year's forum is "Chinese Modernization and the Outlook for China's Economy in the 15th Five-Year Plan." The forum featured a main plenary session and nine parallel forums, including "New Landscape of Global Economy and Trade: Opportunities and Challenges of Going Global," "Alignment of Rules and Mechanisms: Promoting Market Integration in the Greater Bay Area," and "Seeking Strength from the Sea: New Prospects for the Marine Economy." Pre-forum research activities on related themes were also organized. Several economists and entrepreneurs, including Huang Qifan, Academic Advisor of the China Finance 40 Forum and former Mayor of Chongqing; Long Guoqiang, Vice President of the Development Research Center of the State Council; Wang Xiangming, Chairman of China Resources Group; Henry Fok, Executive President of Fok Ying Tung Group; and Dong Mingzhu, Chairwoman of Gree Electric Appliances, were invited to attend and discuss the new blueprint for China's economic development.

At the parallel forum on "High-Quality Hospital Development and Technological Innovation," hosted by People's Daily Health Client, Efung Capital CEO Zhu Pai was invited to speak on a roundtable forum themed "Planning for the '15th Five-Year Plan': Co-building an Industrial Investment and Regional Collaborative Ecology," engaging with peers to discuss regional collaboration and high-quality industrial development.

Seizing the Strategic Opportunities of the "Healthy Greater Bay Area"

Building a New Ecosystem for Industrial Empowerment

Zhu Pai noted that the Guangdong-Hong Kong-Macao Greater Bay Area has created an exceptional policy environment for biopharmaceutical innovation. Taking Shenzhen as an example, the city not only offers numerous preferential policies for foreign-funded enterprises, including tax reductions, but also promotes two-way policy and mechanism alignment through the joint construction of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone, enabling innovation entities to benefit from the institutional advantages of both regions simultaneously.

As the market valuation system gradually returns to rationality, more capital is being directed toward early-stage scientific research translation and startup teams, with greater emphasis on cultivating long-term value and making strategic layouts in cutting-edge fields. Under this trend, building systematic and deep industrial empowerment capabilities has become a key lever for venture capital institutions to serve the national strategy of technological self-reliance and support high-quality development of the real economy.

As a professional venture capital institution deeply rooted in the Guangdong-Hong Kong-Macao Greater Bay Area for the long term, Efung Capital has always adhered to the philosophy of "open exploration, precise focus," continuously deepening its presence in the healthcare field. While actively paying attention to the implementation of AI medical applications, the institution is also proactively laying out emerging tracks with significant clinical value.

Leveraging the "Frontier Ecosystem" Strategy

Supporting China's Path to Becoming a Pharmaceutical Power

The year 2025 stands at a historic intersection, marking the conclusion of China's "14th Five-Year Plan" and the planning of the "15th Five-Year Plan." Amid the profound restructuring of the global technological competition landscape, the strategic position of the biopharmaceutical industry is more prominent than ever, accelerating China's transformation from a "major pharmaceutical country" to a "pharmaceutical power." Against this backdrop, seizing the high ground in biotechnology and achieving high-level technological self-reliance has become a core strategic task for high-quality development and the health and well-being of the nation's people.

Looking ahead to the "15th Five-Year Plan," Efung Capital will closely follow the national strategic deployment in life sciences and biotechnology, adhering to the guiding principles of "global vision, frontier layout, and deep empowerment." The firm will accelerate the construction of a forward-looking project incubation and translation network, systematically supporting Chinese biopharmaceutical enterprises in their transition from following to running alongside and ultimately leading the pack, contributing the power of private capital to China's journey toward becoming a pharmaceutical power.